Prognostic significance of immune reconstitution following CD19 CAR T‐cell therapy for relapsed/refractory B‐cell lymphoma

Abstract Immune deficits after CD19 chimeric antigen receptor (CAR) T‐cell therapy can be long‐lasting, predisposing patients to infections and non‐relapse mortality. In B‐cell non‐Hodgkin lymphoma (B‐NHL), the prognostic impact of immune reconstitution (IR) remains ill‐defined, and detailed cross‐p...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Sophia Stock, Veit L. Bücklein, Viktoria Blumenberg, Giulia Magno, Alica‐Joana Emhardt, Alessandra M. E. Holzem, David M. Cordas dos Santos, Christian Schmidt, Stefanie Grießhammer, Lisa Frölich, Sebastian Kobold, Michael vonBergwelt‐Baildon, Kai Rejeski, Marion Subklewe
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Wiley 2025-01-01
Saila:	HemaSphere
Sarrera elektronikoa:	https://doi.org/10.1002/hem3.70062
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!